

**PQRI Workshop:**

***TiO<sub>2</sub> Use in Pharmaceuticals***

***Global Regulatory and Technical Challenges***


June 13-14, 2023

What could be next?:  
e.g. E172

**PQRI Workshop:  
TiO<sub>2</sub> Use in Pharmaceuticals – Global Regulatory and  
Technical Challenges**

**14 June 2023**

Thomas Broschard, EMD Serono



**MERCK**

# E172

## Agenda

1. Nanomaterials in Food: The ANSES list
2. E172 What and Where?
3. EFSA Opinion/Requests and Consortium
4. Studies and Results
5. Summary & Conclusion

# E172

## Ban of E171: End or Beginning?

*“Substances that occur in human food and for which the presence of manufactured nanomaterials has been proven (characterization using EM in data and literature)”*



EU No.	Chemical name
E 170	Calcium carbonate
E 171	Titanium dioxide
E 172 i, ii, iii	Iron oxide
E 341	Calcium monohydrogen phosphate
E 551	Silicon dioxide
E 552	Calcium silicate
	organic compounds and composites (nanoemulsions, liposomes, micelles, nanocapsules, nanoparticles of lipids)

# E172

## Ban of E171: End or Beginning?

*"substances present in human food and for which the presence of manufactured nanomaterials is suspected and not confirmed after review of the literature and data"*




EU No.	Chemical name
E 173	Aluminum
E 341	Calcium phosphate
E 343	Magnesium phosphate
E 421	Mannitol
E 504	Magnesium carbonate
E 554	Sodium aluminosilicate
	....and many others (30 compounds)
	<a href="https://www.anses.fr/fr/system/files/ERCA2016SA0226Ra.pdf">https://www.anses.fr/fr/system/files/ERCA2016SA0226Ra.pdf</a>



# E172 What?...

Red Iron Oxide  
 $\text{Fe}_2\text{O}_3$

Yellow Iron Oxide  
 $\text{FeO}(\text{OH}) \cdot \text{H}_2\text{O}$




Black Iron Oxide  
 $\text{FeO} \cdot \text{Fe}_2\text{O}_3$

## and Where?



# E172 Timetable



EFSA  
Opinion on  
E172

Studies  
performed

EFSA Nano  
Guidance



Tel Conf.  
with EFSA  
02/2022

Further studies  
performed




E172  
Consortium  
Signed by  
members

Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2022



Data Submission to  
EFSA 12/2022



# E172

## EFSA Opinion 2015



*The Panel recommended that the minimum, Tier 1 testing according to the EFSA guidance (2012), should be conducted for the material as marketed as the food additive (E 172):*



- In vivo genotoxicity at the site of contact (gastrointestinal tract) and subchronic toxicity
- complete set of genotoxicity studies and subchronic toxicity
- absorption, distribution, metabolism and excretion (ADME), in vivo genotoxicity and subchronic toxicity

# E172 Timetable



EFSA  
Opinion on  
E172


Studies  
performed

EFSA Nano  
Guidance



Tel Conf.  
with EFSA  
02/2022


Further studies  
performed



Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2022



Data Submission to  
EFSA12/2022





E172

## Consortium Members



# E172 Timetable



EFSA  
Opinion on  
E172



EFSA Nano  
Guidance



Tel Conf.  
with EFSA  
02/2022

Further Studies  
performed



2015

2016

2017

2018

2019

2020

2021

2022

2023




E172  
Consortium  
signed by  
members

Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2022



Data Submission to  
EFSA12/2022



# E172

## Toxicological Studies Performed



Red

In vivo Comet Assay (OECD 489)  
Rat, oral



Black

In vivo Comet Assay (OECD 489)  
Rat, oral

90-day oral toxicity, rat (OECD 408)



Yellow



Ames test (OECD 471)

HPRT (OECD 476), L5178Y cells

In vitro MNT (OECD 487), CHO cells

Cellular Uptake (Leeds)


90-day oral toxicity, rat (OECD 408)

-  In vivo
-  In vitro


- All studies performed under GLP and according to OECD Guidelines (exception: Cellular uptake)
- Submission in 03/2020

# E172

## In vivo Comet Assay (OECD 489)



- Male rats, 6/group
- Dose levels: 500, 1,000 and 2,000 mg/kg bw/day
- 2 oral admin. (day 1,2)
- Vehicle: 0.5% HPMC
- Stomach and Duodenum
  
- Red E172: Clearly negative in both organs
- Black E172: Clearly negative in duodenum, Highest dose resulted in increase of tail intensity in stomach of 2/6 animals. However, considered to be an artefact and biologically not relevant




Tan & Bajo (2014) Arch Toxicol



E172

# 90-day Oral Toxicity Study (OECD 408)



or



Treatment: 13 weeks



Recovery: 4 weeks



- Rats (m/f)
- Dose levels:  
0, 100, 300 and 1,000 mg/kg bw/day
- 10 animals/sex/group
- Vehicle: Diet
  
- Results:
- No adverse effects up to the highest dose
- No aberrant crypt foci
- NOAEL = 1,000 mg/kg bw/day

## Investigations:

- Clinical symptoms
- Functional Observation Battery
- Body weight and body weight gain
- Food/water consumption
- Hematology, clinical chemistry
- Urinalysis
- Gross necropsy
- Organ weights
- Histopathology
- Aberrant Crypt Foci
- Toxicokinetics



# E172

## In Vitro Genotoxicity with



### Test

- **OECD 471** (Ames test)  
up to 5,000 µg/plate  
+/- S9




---

- **OECD 476** (HPRT test)  
gene mutation  
L5178Y mouse lymphoma cells  
up to 100 µg/mL, +/-S9

---

- **OECD 487** (in vitro MNT test)  
clastogenicity/aneugenicity  
CHO cells  
up to 300 µg/mL, +/-S9

---

### Result

- Negative  
(not relevant for insoluble particles)

---

- Negative

---

- Negative

---

# E172

## In vitro Cellular Uptake



### Swansea University & University of Leeds

**L5178Y cells** (HPRT):

No cellular uptake,  
test material attached to cell surface




Figure 5 – Example electron micrographs of L5178Y cells treated with 100.1 µg/ml IRON OXIDE SICOVIT® YELLOW 10 E172. (A) - TEM image of L5178Y cells showing the presence of the test material at the cell surface (highlighted by the red arrows and the red box). No evidence of cellular uptake of test material is visible. The region highlight in the red box is displayed in (B) at higher magnification, the red arrow showing the location and morphology of the test material.

**CHO cells** (in vitro MNT):

Clear cellular uptake




Figure 11 – Example electron micrographs of CHO cells treated with 75 µg/ml IRON OXIDE SICOVIT® YELLOW 10 E172. (A) - TEM image showing localisation of the test material in CHO cells highlighted by the red arrows and the red box). The region highlight in the red box is displayed in (B) at higher magnification, the red arrows showing membrane bound test material (i) and test material free in the cytoplasm (ii).

# E172 Timetable




2015                      2016                      2017                      2018                      2019                      2020                      2021                      2022                      2023



EFSA  
Opinion on  
E172

Studies  
performed

EFSA Nano  
Guidance




Tel Conf.  
with EFSA  
02/2022

Further Studies  
performed




E172  
Consortium  
signed by  
members

Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2021




Data Submission to  
EFSA12/2022





# E172

## EFSA Request for Clarification (11/2022)





*Request for clarifications on the data submitted for the assessment on iron oxides and iron hydroxides (E 172):*

- Physicochemical Characterisation
  - Composition, Coating, Particle Size Analysis
- Safety evaluation strategy and corresponding testing strategy
  - Reference to EFSA SC Guidance on particle-TR
  - *...you are invited to provide scientific evidence, supported by data, confirming that the safety studies provided for the assessment of E 172 are adequate for addressing the safety of the fraction of small particles, including nanoparticles, according to the principles indicated in Section 4 of the EFSA SC Guidance on particle-TR. P*
  - *...demonstrate that the test material(s) used in the safety studies included the fraction of small particles*
  - *demonstrate the adequacy of the study design of the existing toxicity and genotoxicity studies for covering the hazard assessment of the fraction of small particles,*



# E172

## Vehicles and Preparations (in vivo)

Study	Test Item	Vehicle	Dose/Conc.	Comment
90-day, oral rat (OECD 408)		Diet (ssniff®-R/M-H V1530, ssniff® Spezialdiäten GmbH, 59494 Soest, Germany)	100, 300, 1,000 mg/kg bw/day (1, 5 and 20 g/kg diet)	Premix, mixer (Röhrnradmischer)
In vivo Comet Assay (OECD 489)		Aqueous Hydroxypropyl methylcellulose 0.5%	500, 1,000, 2,000 mg/kg bw/day (50, 100, 200 mg/mL)	<i>The test article was weighed into a formulation bottle. Vehicle was added to achieve the final volume. Formulations were then vortex mixed to stir</i>

# E172

## Vehicles and Preparations (in vitro)

Study	Test Item	Vehicle	Dose/Conc.	Comment
HPRT (OECD 476) L5178Y Mouse lymphoma cells		RPMI 1640 with additives and 5% horse serum	0.2-100 µg/mL	Vortex, ultrasonication, warming
In vitro MNT (OECD 487)		McCoy's 5A Medium +10% FCS	<300 µg/mL	Mixing

# E172 Timetable



EFSA  
Opinion on  
E172

Studies  
performed

EFSA Nano  
Guidance



Tel Conf.  
with EFSA  
02/2022



Further Studies  
performed

2015      2016      2017      2018      2019      2020      2021      2022      2023




E172  
Consortium  
signed by  
members

Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2021



Data Submission to  
EFSA12/2022







# E172 Particle Characterization




- Preparation of test item/diet mixtures comparable to in vivo/in vitro studies
- Analysis by SEM
- Nanofraction in tox studies comparable to or exceeding real samples

E172 Yellow in rat diet  
(0.5%)



E172 Yellow in water  
(1 mg/mL)



## % Nano fraction


Rat diet	Gentox in vitro	Capsule	Hard candy shell
51-66.7%	30.2%	1.4 – 3.7%	42.5%

# E172 Particle Characterization





- Preparation of test item/diet mixtures comparable to in vivo studies
- Analysis by SEM
- % Nano fraction exceeds real samples

E172 Black in 0.5% HPMC  
(5 mg/mL)



E172 Black in rat diet  
(2.3 %)



% Nano fraction


Rat diet	0.5% HPMC	Capsule	Hard candy shell
8-11%	28%	0-2.1%	0%

# E172

## Particle Characterization



E172 Red in 0.5% HPMC  
(0.5 %)



- Preparation of test item in Methocel comparable to in vivo studies
- Analysis by SEM
- % nanofraction comparable to real sample

% Nano fraction

0.5% HPMC	Capsule
6.3%	4.1-6.5%

# E172 Timetable



EFSA  
Opinion on  
E172

Studies  
performed

EFSA Nano  
Guidance




Tel Conf.  
with EFSA  
02/2022

Further Studies  
performed




E172  
Consortium  
signed by  
members

Data  
Submission  
to EU COM  
03/2020



EFSA  
Request for  
further data  
11/2021



Data Submission to  
EFSA12/2022





# E172

## Summary & Conclusion

- In 2015, Efsa has identified data gaps for three different E172 qualities; red, yellow and black
- An Industry Consortium has been formed which performed all studies requested by EFSA
- Based on the studies performed (and literature data) no adverse effect/no hazard has been identified for red, black or yellow E172
- Additional analytical investigations showed that the % nano fraction in the different test item formulation are comparable to real samples
- Based on the available data, red, yellow and black E172 are considered to be safe for food and pharmaceuticals
- EFSA opinion is expected to be published in 2024



E172

## Acknowledgments

**VENATOR**

- Martin Zilse
- Mark Booth
- Markus Rohe
- David Lockley

**EBRC**   
Consulting GmbH

- Andreas Westphal
- Arne Burzlaff
- Roger Battersby

**JONES  
DAY**®

- Ursula Schliessner
- E172 Consortium

**Colorcon** 

- Kevin Hughes

**Capsugel**® | **LONZA**

- Bram Baert

**...and you for your attention**